Literature DB >> 25494264

Macular hemorrhage as a cause of acute angle closure - Photodynamic therapy and polypoidal choroidal vasculopathy.

Gwyn Samuel Williams1, Luke Anderson, David J Eddyshaw.   

Abstract

Entities:  

Year:  2014        PMID: 25494264      PMCID: PMC4290213          DOI: 10.4103/0301-4738.146746

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


× No keyword cloud information.
Dear Sir, We are very grateful for the interest shown in our article by the above contributor.[12] Fundus fluorescein angiography (FFA) was indeed performed and although the images demonstrated an occult leakage, the quality was such that detailed interpretation was not possible due to the masking effect of the blood. Your contributors are correct in that it has long been known that indocyanine green angiography has long been demonstrated as being superior to FFA in macular degeneration cases involving hemorrhages although, in this case, the images were also deemed unhelpful due to the blood.[3] Whereas the EVEREST study did indeed show statistically significant differences in rates of polyp regression in polypoidal choroidal vasculopathy (PCV), the functional outcomes did not demonstrate any significant differences between photodynamic therapy with verteporfin (PDT) and intravitreal ranibizumab.[4] Indeed, it has been recently suggested that intravitreal ranibizumab offers superior functional outcomes over PDT in treating patients with PCV.[5] In the case of our patient, however, the visual acuity did not improve beyond counting fingers despite intravitreal ranibizumab therapy, and the jury is probably still out in knowing the best course of action in patients with PCV presenting with significant hemorrhage, although it is probably safe to deduce that the functional outcome is not likely to be satisfactory if the hemorrhage is very large in any case. We wholeheartedly agree with the comments that this kind of presentation of macular hemorrhage is in all probability underreported and under recognized and are grateful for the supportive comments that serve to further highlight this issue.
  5 in total

1.  Long-term outcome of intravitreal ranibizumab treatment, compared with photodynamic therapy, in patients with polypoidal choroidal vasculopathy.

Authors:  M Inoue; A Arakawa; S Yamane; K Kadonosono
Journal:  Eye (Lond)       Date:  2013-08-23       Impact factor: 3.775

2.  EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.

Authors:  Adrian Koh; Won Ki Lee; Lee-Jen Chen; Shih-Jen Chen; Yehia Hashad; Hakyoung Kim; Timothy Y Lai; Stefan Pilz; Paisan Ruamviboonsuk; Erika Tokaji; Annemarie Weisberger; Tock H Lim
Journal:  Retina       Date:  2012-09       Impact factor: 4.256

3.  Clinical application of indocyanine green angiography to choroidal neovascularization.

Authors:  K Hayashi; Y Hasegawa; Y Tazawa; J J de Laey
Journal:  Jpn J Ophthalmol       Date:  1989       Impact factor: 2.447

4.  Massive submacular hemorrhage resulting in acute angle closure.

Authors:  Wei Kiong Ngo; Kai Xiong Cheong; Colin S H Tan
Journal:  Indian J Ophthalmol       Date:  2014-07       Impact factor: 1.848

5.  Macular hemorrhage as a cause of acute angle closure.

Authors:  Gwyn Samuel Williams; Luke Anderson; David Eddyshaw
Journal:  Indian J Ophthalmol       Date:  2013-11       Impact factor: 1.848

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.